Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2022 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second...
May 17, 2022 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Participate in H.C. Wainwright Global Investment Conference

STOUGHTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will...
May 10, 2022 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports First Quarter 2022 Financial Results

- Generated Net Revenue of $83.8 Million - - Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million - - Resolved All Opioid-Industry Litigation - -...
April 26, 2022 16:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results

STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will...
April 07, 2022 16:47 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Participate in Upcoming Needham Healthcare Conference

STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will...
April 06, 2022 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Appoints Neil McFarlane to its Board of Directors

STOUGHTON, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the appointment of Neil...
April 05, 2022 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Provides 2022 Financial Guidance

– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA...
March 30, 2022 08:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending...
March 22, 2022 17:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Completes the Acquisition of BDSI

STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences...
February 24, 2022 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA...